研究单位:[1]复旦大学附属华山医院[2]吉林大学第一医院[3]首都医科大学宣武医院[4]四川省人民医院[5]福建医科大学附属协和医院[6]香港大学深圳医院[7]山西医科大学第一医院[8]贵州医科大学附属医院[9]广东省中医院[10]广州中医药大学第一附属医院[11]宁波市医疗中心李惠利医院[12]重庆医科大学附属第一医院[13]山东大学齐鲁医院(青岛)[14]华中科技大学同济医学院附属同济医院[15]广西医科大学第一附属医院[16]HonorHealth Neurology - Bob Bove Neuroscience Institute[17]Loma Linda University Health[18]First Choice Neurology Boca Raton[19]SFM Clinical Research LLC[20]The Neurology Institute / Healthcare Innovations Institute - Coral Springs[21]Neurology Associates PA[22]University of Miami Miller School of Medicine[23]Medsol Clinical Research Center Inc[24]BayCare - St. Anthony's Hospital[25]University of South Florida (USF) Health - Morsani Center for Advanced Healthcare[26]Wellstar - Augusta University Medical Center[27]Northwestern Medicine - Northwestern Memorial Hospital[28]Kansas University Medical Center - Kansas City[29]Massachusetts General Hospital[30]Henry Ford Health - Henry Ford Hospital[31]Saint Louis University[32]Rutgers-Robert Wood Johnson Medical School[33]University of North Carolina - Chapel Hill[34]Carolinas HealthCare System Neurosciences Institute-Neurology[35]Duke University School of Medicine - Duke Early Phase Clinical Research Unit[36]Cleveland Clinic[37]Penn Presbyterian Medical Center[38]Erlanger Neuroscience Institute[39]National Neuromuscular Research Institute[40]Virginia Commonwealth University[41]University of Washington Medical Center - Montlake[42]West Georgia Medical Center[43]Pineo Medical Ecosystem[44]New Hospitals[45]LLC Caucasus Medical Centre
研究目的:
在 A 部分中,确定 Efgartigimod IV 相较于安慰剂在 AChR-Ab 血清阴性 gMG受试者中的有效性